Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

ss and products. These and other risks are discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2006, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of this release, and Myriad undertakes no duty to update this information unless required by law.

Contact:
William A. Hockett
EVP, Corporate Communications
(801) 584-3600
Email Contact





'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:5/15/2008)...RIAS HR Pilot Study Compares Genous, Boston Scient...her Presentations Focus on Real-World Use of Genou...e Who Could Not Tolerate Dual-Antiplatelet ..., May 15 /- OrbusNeich today announce...ymposium at EuroPCR 2008,support the use of the co...
(Date:5/15/2008)...is., May 15 /- Omega 3 fatty acids bo...ered as a credible natural,alternative and may hav...s,recent in vivo French study reveals. While seve...ega-3 in hyperactivity, French researchers have,hy...ositive effects on,impulse control., These resear...
(Date:5/14/2008)...ass., May 14 /- Biopure Cor... results from its Phase II coronary,revascularizat...,EuroIntervention Journal. The paper is entitled "...ed oxygen therapeutics in elective percutaneous,co...gn, and haemodynamic,results." The manuscript was ...
(Date:5/14/2008)... experts to be important for cervical cancer preve...l/ -- New data from an,extended follow-up study sh...cer candidate vaccine, CERVARIX(R) generates susta...t the two most common cervical cancer-causing,huma...s the longest,duration of sustained neutralizing a...
Breaking Medicine Technology:Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 1Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 1Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 4New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 328 1New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 328 2New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 328 3New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 1New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 2New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 3New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 4New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 5
...0, 2007 - Valeant,Pharmaceuticals International (N...2 data for retigabine, a first-in-class,neuronal p...ndependent, scientific journal. The authors conclu...rated reduction in monthly,seizure rates in this s...TORE2) are currently underway to further investiga...
...2007 - The two most,prevalent forms of genetic men... share a common cause, according to researchers at...em, a crippled,communication network in the brain,... genetics of the disorders are very different, the...id Daniel Madison,PhD, associate professor of mol...
Other Medicine Technology:Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4
(Date:5/16/2008)...tment of Nomura Code Securities Limited as ... YORK, May 16 /PRNewswire-FirstCall/ -- Medicsight.... (Amex: MGT ) (the "Company"), and an,industry l...on (CAD) and,image analysis software which assists...today announced the appointment of NM Rothschild &...
(Date:5/16/2008)...ewswire/ -- Barbara Senich, B.S.N., M.B.A.,M.P.H....es, was honored by,Executive Women of New Jersey (...ards Dinner. The biennial event, held May 15, 2008...men of professional distinction in New,Jersey who ...ctors at major,New Jersey-based corporations and o...
(Date:5/16/2008)...inhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuti...("Genesis" or,the "Company"), a leading pharmaceut...day announced that it had donated medicines with a...28,000) to Sichuan Earthquake relief.,These medici... Beijing,Time., "We are extremely grieved to know...
(Date:5/16/2008)...and efficacy of first FDA-approved nebulized f...vere COPD -, NAPA, Calif., May 16 /PRNewswire/ --...a presentations will be given at the International... on May 20, 2008 at the,Metro Toronto Convention C...s on dyspnea and other COPD symptoms of using Perf...
Breaking Medicine News(10 mins):Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Roche Vice President Senich Honored at EWNJ 'Salute to Policy Makers' 2Health News:Roche Vice President Senich Honored at EWNJ 'Salute to Policy Makers' 3Health News:Genesis Pharmaceuticals Donates Medicine to China Sichuan Earthquake Relief 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 4Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 5
...r may delay your chances of getting treated// for ...he British Journal of Cancer, valuable time is los...nosis gets delayed. Patients with suspected prosta...es later than those with breast cancer patients wh...
...hed the association between adult urinary incontin...more than 1000 Turkish women, the research says th... the same for exhibiting lack of control in contro...rs feel that these women may suffer from some faul...
...first direct association of faulty metabolism with...rallels from an animal study. Atherosclerosis or c... substances, cholesterol, cellular waste products,...r lining of the arteries. This build up is called ...
...tsburgh had said in a new study that there’s adequ...ith age, in spite of the elderly frequenting the b...dder capacity and stability, urethral closure pres...ontraction strength from 95 females of ages 22 to ...
Other Medicine News:
... Novametrix' family of capnography products. Along...handheld, mainstream capnographs available today, ...rway condition and ventilatory status. Based on th...iniaturized the size, not the performance. TIDAL W...
The Models 512 and 513 handheld pulse oximeters incorporate "digital signal processing. This advanced technology is able to process pulsatile signals at much higher resolutions and speeds of 100 time
...ulse Oximeter is a one-of-a-kind oximeter that off...tion of the N-20PA has been shock-tested, vibratio... conditions it has even withstood the rigors of M... check measurements and also useful for continuous...
...er with Oxismart XL Advanced Signal Processing rea...through nonspecific noise to find the pulse and tr... N395 monitor is also equipped with SatSeconds Ala...mable alarm sensitivity for pulse oximetry. SatSec...
Medicine Products: